Vanda Pharmaceuticals Inc. (VNDA) Report Analysis
Corporate Events
Vanda Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $10.307 million.
2022-06-17 00:00:00
Vanda Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $10.307 million. Security Name: Common Stock Securities Offered: 1,100,000 Transaction Features: ESOP Related Offering
Vanda Pharmaceuticals Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 03:30 PM
2022-06-03 04:03:00
Vanda Pharmaceuticals Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 03:30 PM. Venue: Marriott Marquis, New York City, New York, United States.
Vanda Pharmaceuticals Inc. Presents at SLEEP 2022, Jun-07-2022 05:15 PM
2022-05-31 22:00:00
Vanda Pharmaceuticals Inc. Presents at SLEEP 2022, Jun-07-2022 05:15 PM. Venue: Charlotte, North Carolina, United States. Speakers: Sandra Paulina Smieszek, Head of Genetics.
Vanda Pharmaceuticals Inc. Presents at DDW 2022- Digestive Disease Week, May-21-2022 through May-24-2022
2022-05-20 00:00:00
Vanda Pharmaceuticals Inc. Presents at DDW 2022- Digestive Disease Week, May-21-2022 through May-24-2022. Venue: San Diego Convention Center, San Diego, California, United States. Presentation Date & Speakers: May-21-2022, Sandra Paulina Smieszek, Head of Genetics. May-23-2022, Sandra Paulina Smieszek, Head of Genetics.
Vanda Pharmaceuticals Inc. Provides Financial Guidance for the Year 2022
2022-05-05 20:10:00
Vanda Pharmaceuticals Inc. provided financial guidance for the year 2022. For the year, the company expects total revenues to be in the range of $240 to $280 million.
Vanda Pharmaceuticals Inc., Q1 2022 Earnings Call, May 05, 2022
2022-04-28 21:00:00
Vanda Pharmaceuticals Inc., Q1 2022 Earnings Call, May 05, 2022
Vanda Pharmaceuticals Inc. to Report Q1, 2022 Results on May 05, 2022
2022-04-28 21:00:00
Vanda Pharmaceuticals Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022
Vanda Pharmaceuticals Inc. - Shareholder/Analyst Call
2022-04-25 20:33:00
Annual Meeting of Stockholders
Vanda Pharmaceuticals Inc., Annual General Meeting, Jun 16, 2022
2022-04-25 20:33:00
Vanda Pharmaceuticals Inc., Annual General Meeting, Jun 16, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect Stephen Ray Mitchell to serve as the Class I director until the 2025 annual meeting of stockholders; to ratify the selection by the Audit Committee of the Company's Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2022; to approve on an advisory basis the named executive officer compensation; to approve an amendment to the Company's Amended and Restated 2016 Equity Incentive Plan, as amended, to increase the aggregate number of shares authorized for issuance under the 2016 Plan; and to conduct any other business properly brought before the Annual Meeting or any adjournments or postponements thereof.
H. Thomas Watkins Not Stands for Reelection of Vanda Pharmaceuticals Inc
2022-04-25 20:33:00
Mr. H. Thomas Watkins has informed the Board of Vanda Pharmaceuticals Inc. that he will not stand for re-election and his term will expire on June 16, 2022 following the Annual Meeting.
Vanda Pharmaceuticals Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 04:00 PM
2022-03-22 05:03:00
Vanda Pharmaceuticals Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 04:00 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Kevin Patrick Moran, Senior VP, CFO & Treasurer.
Research Diets, Inc., DDW 2022- Digestive Disease Week, May 21, 2022 through May 24, 2022
2022-02-24 13:30:00
Research Diets, Inc., DDW 2022- Digestive Disease Week, May 21, 2022 through May 24, 2022. Venue: San Diego Convention Center, San Diego, California, United States.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
Vanda Pharmaceuticals Inc. Reports Results from the Phase III Study of Tradipitant in Gastroparesis
2022-02-04 12:00:00
Vanda Pharmaceuticals Inc. announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis. The study did not meet its prespecified primary endpoint which was the difference between drug and placebo on the change of the severity of nausea from baseline at week 12 of treatment. Both treatment arms showed significant improvements from baseline on nausea as well as the other core symptoms of gastroparesis. Initial exploratory analysis has identified potential confounders that may have masked the beneficial effect of the drug previously observed in the Phase II study of tradipitant, which include a baseline imbalance of rescue medication use between the two treatment arms as well as an observed poor compliance with study drug for some patients in the study. When restricting the analysis in the group of patients that used no rescue medications at baseline and adjusting for poor compliance, Vanda identified strong evidence of a drug effect across a number of symptoms and across the duration of the study, including a significant and meaningful effect at the prespecified primary endpoint of nausea change at week 12. The Phase III study also continued to demonstrate that tradipitant is safe and well-tolerated, as seen in previous studies over the 12 weeks of treatment. Patients on tradipitant experienced a similar number of treatment emergent adverse events as patients receiving placebo. The most common adverse event where tradipitant frequency was higher than placebo was diarrhea. Patients that participated in the clinical program also had the opportunity to seek expanded access to tradipitant based on the benefit in the study and their individual unmet medical needs. Ten patients have received more than 3 months of tradipitant treatment, 6 of whom have received at least 1 year of tradipitant treatment.
Vanda Pharmaceuticals Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 10:00 AM
2021-11-10 23:30:00
Vanda Pharmaceuticals Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 10:00 AM. Venue: New York, New York, United States.
Vanda Pharmaceuticals Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM
2021-11-10 23:30:00
Vanda Pharmaceuticals Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.
Vanda Pharmaceuticals Inc. Revises Financial Guidance for the Year 2021
2021-11-03 20:01:00
Vanda Pharmaceuticals Inc. revised financial guidance for the year 2021. For the year, it revises total revenues of $260 to $290 million compared to $270 to $300 million prior guidance.
Vanda Pharmaceuticals Inc. Presents at BioData World Congress 2021, Nov-03-2021 12:00 PM
2021-10-28 15:58:00
Vanda Pharmaceuticals Inc. Presents at BioData World Congress 2021, Nov-03-2021 12:00 PM. Speakers: Sandra Smieszek, Head of Genetics.
Vanda Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 03, 2021
2021-10-27 21:30:00
Vanda Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 03, 2021
Vanda Pharmaceuticals Inc. to Report Q3, 2021 Results on Nov 03, 2021
2021-10-27 21:30:00
Vanda Pharmaceuticals Inc. announced that they will report Q3, 2021 results After-Market on Nov 03, 2021
Vanda Pharmaceuticals Inc. Announces Resignation of Aranthan “Aj” Jones II as the Corporate Affairs and Communications Officer
2021-10-08 20:07:00
On October 6, 2021, Aranthan “AJ” Jones II notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Corporate Affairs and Communications Officer, effective as of October 26, 2021, in order to join a U.S.-based, publicly traded company outside of the biopharmaceutical sector.
Terrapinn Holdings Ltd, BioData World Congress 2021, Nov 02, 2021 through Nov 04, 2021
2021-10-06 12:29:00
Terrapinn Holdings Ltd, BioData World Congress 2021, Nov 02, 2021 through Nov 04, 2021.
Vanda Pharmaceuticals Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021
2021-09-01 19:46:00
Vanda Pharmaceuticals Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.
Vanda Pharmaceuticals Closes Enrollment in the ODYSSEY Study Comparing Tradipitant and Placebo in Hospitalized COVID-19 Pneumonia Patients
2021-08-03 11:00:00
Vanda Pharmaceuticals Inc. announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint. The study was designed to determine whether tradipitant plus standard of care is superior to placebo plus standard of care in treating hospitalized patients with COVID-19 pneumonia who required supplemental oxygen support. The primary endpoint of the study is the difference between treatment and placebo on time to 2-point improvement on a 7-point ordinal scale. Treatment duration was 14 days and evaluation for the primary endpoint was at Day 28. Additional secondary endpoints include other changes in clinical and laboratory status. An independent data and safety monitoring board met to assess the planned interim analysis results. The DSMB determined that the study is unlikely to show a significant difference between treatment arms at the pre-specified primary endpoint and recommended termination of the study for futility. The DSMB also determined that there are no safety concerns that contributed to its recommendation. The ODYSSEY study was initiated in April 2020 with an enrollment goal of 324 patients of which 153 have enrolled to date. Separately, Vanda will continue the genetics component of the study with the goal of identifying genetic susceptibility factors contributing to the incidence of severe pneumonia among patients infected with the SARS-CoV-2 virus. In pursuit of that goal, Vanda has recently reported in the Journal of Global Antimicrobial Resistance on loss of function mutations in the IFNAR2 gene associated with COVID-19 severe infection susceptibility.
Vanda Pharmaceuticals Inc. Provides Sales Guidance for the Year 2021
2021-07-28 20:01:00
Vanda Pharmaceuticals Inc. provided sales guidance for the year 2021. For the year, it expects total revenues of $270 to $300 million.
Vanda Pharmaceuticals Inc., Q2 2021 Earnings Call, Jul 28, 2021
2021-07-21 20:30:00
Vanda Pharmaceuticals Inc., Q2 2021 Earnings Call, Jul 28, 2021
Vanda Pharmaceuticals Inc. to Report Q2, 2021 Results on Jul 28, 2021
2021-07-21 20:30:00
Vanda Pharmaceuticals Inc. announced that they will report Q2, 2021 results After-Market on Jul 28, 2021
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021
2021-07-08 08:44:00
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.
Fundamental Summary
Looking at Vanda Pharmaceuticals's financials of Q1 reflected unimpressive, mediocre results. It is highly likely that the company will be mostly tethered to market performance and sector movements for the near term. We gave Vanda Pharmaceuticals a 62 rating and a HOLD recommendation.
Vanda Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 60.19 million compared to USD 62.67 million a year ago. Net loss was USD 6.43 million compared to net income of USD 8.65 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to basic earnings per share from continuing operations of USD 0.16 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to diluted earnings per share from continuing operations of USD 0.15 a year ago.
Business Description
Vanda Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company’s products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Sector Overview
Vanda Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Vanda Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 3.7 | -46.1% | 81 | |
| Net Cashflow | -5.3 | 41.6% | 66 | |
| Capital Expenditure | -0.5 | 10.0% | 87 | |
| Asset Turnover | 0.5 | -2.6% | 51 | |
| Free Cashflow | 1.0 | -8.4% | 60 |
* All values are TTM
The below chart reflects Vanda Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Vanda Pharmaceuticals's peer average final assessment score stands on 68.0, Vanda Pharmaceuticals's score is 62.
- VNDA
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Vanda Pharmaceuticals's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Vanda Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.
5D MA
10.6
50D MA
10.1
200D MA
13.93
MACD
0.12
RSI
7.42
STOCH
88.36
Balance Sheet Analysis
Overall, Vanda Pharmaceuticals's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Vanda Pharmaceuticals reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 66.9, representing 28.5% change from the last report. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their cash and cash equivalents movement received a grade of 89. Also, In terms of liabilities, Vanda Pharmaceuticals published good numbers. Their reported liabilities were 101.4, representing a 14.1% change from the previous report. This performance is all interesting relative to their peers and suggests that their stock price has room to grow to reflect a higher intrinsic value. Therefore, we rated their liabilities movement with a score of 82. On the other hand, Equity, jumped out as looking rather underwhelming. Vanda Pharmaceuticals published concerning equity metrics for this filing. In the current report, equity stood at 502.1, which represents a -0.6% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Consequently, their equity movement received a grade of 47. Therefore, their balance sheet earned a grade of 64.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 603.6 | 1.6% | 70 |
| Liabilities | 101.4 | 14.1% | 82 |
| Price to Book | 1.1 | -35.2% | 56 |
| Cash & Equivalents | 66.9 | 28.5% | 89 |
| Equity | 502.1 | -0.6% | 47 |
The below chart describes Vanda Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Vanda Pharmaceuticals received a balance sheet score of 64, the average of its peers stands on 65.0.
- VNDA
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 0 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 2 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 5 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 10 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 11 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 12 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 13 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 16 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 18 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 22 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 26 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 27 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 28 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 30 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 40 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 42 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 44 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 47 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 57 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 73 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 74 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 75 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 94 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Two metrics jump up as the most significant positive drivers of the income statement's strength in Vanda Pharmaceuticals's recent report: Revenue Efficiency and Return Factors. Vanda Pharmaceuticals did an excellent job managing its revenue efficiency this past period. Vanda Pharmaceuticals's revenue efficiency is 266.2 according to the metrics in the current filing, which represents a -0.9% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. As a result, its revenue efficiency earned a score of 89. Also, In this filing, Vanda Pharmaceuticals reported a return on equity (ROE) ratio of 3.7, which represents a change of -46.1%. Its return factor metrics are even more remarkable when compared to their peers. Therefore, its return factors component earned a score of 81. That said, one metric, EBITDA, stood out as strongly negative. Vanda Pharmaceuticals's EBIDTA now sits at 29.7 and represents -37.8% change from the last reporting period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Therefore, their EBITDA component earned a score of 46. As the companie's management is doing an excellent job managing the critical metrics, the income statement was given a score of 62.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 29.7 | -37.8% | 46 |
| Total Revenues | 266.2 | -0.9% | 89 |
| Return on Equity | 3.7 | -46.1% | 81 |
The below chart describes Vanda Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Vanda Pharmaceuticals received a income statement score of 62 , the average of its peers stands on 68.0.
- VNDA
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 0 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 2 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 5 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 10 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 11 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 12 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 13 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 16 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 18 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 22 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 26 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 27 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 28 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 30 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 40 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 42 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 47 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 73 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 74 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 94 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Overall, Vanda Pharmaceuticals's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Vanda Pharmaceuticals's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -0.5, which represents a 10.0% change from the last period. This performance is all the more impressive relative to their peers and competitors. The company's CapEx movement, therefore, received a grade of 87. Also, Vanda Pharmaceuticals's strong net cash flow numbers, which were -5.3 in this filing, showed a 41.6% change from the last period. Their net cash flow metrics are especially remarkable relative to their peers. Consequently, their net cash flow movement received a grade of 66. However, one discouraging result, Asset Turnover, stood out. Vanda Pharmaceuticals's asset turnover numbers were discouraging, reflecting significant concerns related to management's ability to leverage assets to generate sales effectively and efficiently. Vanda Pharmaceuticals recorded asset turnover of 0.5, which represents a -2.6% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Correspondingly, their asset turnover movement received a grade of 51. Consequently, its cash flow earned a score of 69.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -5.3 | 41.6% | 66 |
| Capital Expenditure | -0.5 | 10.0% | 87 |
| Asset Turnover | 0.5 | -2.6% | 51 |
| Free Cashflow | 1.0 | -8.4% | 60 |
The below chart describes Vanda Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Vanda Pharmaceuticals received a cash flow score of 69, the average of its peers stands on 71.0.
- VNDA
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 0 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 2 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 5 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 10 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 11 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 12 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 13 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 16 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 18 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 22 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 26 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 27 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 28 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 30 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 40 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 42 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 47 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 73 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 74 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 94 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.